oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics. These tests are then either marketed directly by oncgnostics or out-licensed. Our first product - GynTect - will be launched in the middle of next year and is an IVD reliably detecting cervical (pre-) cancer.